Atlas Trials

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

Clinical trial NCT04179110 · WITHDRAWN

Trial details

NCT number
NCT04179110
Sponsor
Yale University
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Transitional Cell Carcinoma
Start date
2020-09-18
Primary completion
2022-12-15
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.